Reports generated by this project on the potential social and economic
impact of tobacco bio-pharming are given below. Contact our project
coordinator if you have questions or problems linking to the
files listed below.
Be sure to check back periodically for new entries to this page.
Participatory
Assessment of Social and Economic Effects of
Using Transgenic Tobacco to Produce Pharmaceuticals Social and economic perspectives regarding the use of transgenic
tobacco to produce therapeutics are garnered from major stakeholders
using various qualitative data gathering formats.
Potential Impacts of Pharmaceutical Uses of Transgenic Tobacco:
The Case of Human Serum Albumin (HSA)
The potential size and distribution of benefits from transgenic
tobacco as a source of human serum albumin are estimated using an
economic surplus model with imperfect competition. Results suggest
that new products from bio-pharming stand to generate significant
social benefits.
Market Strategies for a Tobacco Bio-Pharming Application: The Case of Gaucher's Disease Treatment This paper explores the expected 'Buyout' price and economic surplus changes for an emerging bio-pharming application with transgenic tobacco. Despite a potentially large payout to the innovating firm, consumers also see significant surplus gains.
This project was supported by Initiative for Future Agriculture and Food Systems
Grant no. 2001-52100-11250 from the USDA Cooperative State Research, Education, and Extension Service
Participatory
Assessment of Social and Economic Effects of
